Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 24;17(1):242.
doi: 10.1186/s13098-025-01783-9.

The role of myocardial fibrosis in the diabetic cardiomyopathy

Jinghui Sun  1 , Ruiling Zhou  2 , Mi Liu  2 , Dawu Zhang  3
Affiliations
Review

The role of myocardial fibrosis in the diabetic cardiomyopathy

Jinghui Sun et al. Diabetol Metab Syndr. .

Abstract

Diabetic cardiomyopathy (DCM), a main cardiovascular complication of diabetes mellitus, can eventually develop into heart failure and seriously affect the prognosis of diabetic patients. Myocardial fibrosis (MF) is the main factor causing ventricular wall stiffness and heart failure in DCM. Early control of MF in DCM is of great significance to prevent or postpone the progression of DCM to heart failure. In this review, we systematically analyzed the relevant studies on diabetic MF in recent years, explored the formation mechanism of MF in the pathological process of DCM, and summarized and analyzed in detail the current studies with antifibrotic treatment for DCM, so as to provide guidance for the development of prevention and treatment strategies for MF in DCM.

Keywords: Cardiovascular complication; Diabetes mellitus; Diabetic cardiomyopathy; Heart failure; Myocardial fibrosis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: All the authors agreed to publish the paper. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The molecular mechanism of MF in DCM
Fig. 2
Fig. 2
Drugs for the prevention and treatment of DCM by regulating TGF-β signaling pathway to inhibit MF
Fig. 3
Fig. 3
Drugs for the prevention and treatment of DCM by regulating oxidative stress and inflammatory responses to inhibit MF
Fig. 4
Fig. 4
Drugs for the prevention and treatment of DCM by regulating other mechanisms to inhibit MF
See this image and copyright information in PMC

References

    1. Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81. - PubMed
    1. Marwick TH, Ritchie R, Shaw JE, et al. Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol. 2018;71(3):339–51. - PubMed
    1. Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30(6):595–602. - PubMed
    1. Matsutani D, Sakamoto M, Kayama Y, et al. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):73. - PMC - PubMed
    1. Lee WS, Kim J. Diabetic cardiomyopathy: where we are and where we are going. Korean J Intern Med. 2017;32(3):404–21. - PMC - PubMed

LinkOut - more resources